NCT05643690 is a clinical trial of UriFind Bladder Cancer Assay in Bladder Cancer, sponsored by AnchorDx Medical Co. Ltd. US.

Who is sponsoring NCT05643690?

NCT05643690 is sponsored by AnchorDx Medical Co. Ltd. US.

What drugs are being tested in NCT05643690?

Interventions in NCT05643690: UriFind Bladder Cancer Assay.

What condition does NCT05643690 study?

NCT05643690 studies Bladder Cancer.

Is NCT05643690 still recruiting?

NCT05643690 is currently suspended. Last updated 6 June 2024.

Last reviewed 2024-06-06 · How we verify

NCT05643690

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

Suspended Last updated 6 June 2024

What this trial tests

trial testing UriFind Bladder Cancer Assay in Bladder Cancer in 77 participants. Suspended.

Timeline

18 November 2022

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	AnchorDx Medical Co. Ltd. US
Status	Suspended
Study type	OBSERVATIONAL
Enrollment	77
Start date	18 November 2022
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	2 locations across United States

Drugs / interventions tested

UriFind Bladder Cancer Assay

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →

Sponsor

AnchorDx Medical Co. Ltd. US

Who can join

Adults 55 to 100, any sex, with Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The AnchorDx UriFind™ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advances in Liquid Biopsy for Diagnosis of Bladder Cancer.
Seok J, Kwak Y, Kim S, Kim EM, et al · · 2024 · cited 6× · PMID 38956768 · DOI 10.5213/inj.2448198.099

Verify or expand the search:

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05643690 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AnchorDx Medical Co. Ltd. US
Last refreshed: 6 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05643690.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing